Advertisement

RANCHO CORDOVA, Calif., Sept. 13 /PRNewswire/ -- ThermoGenesis Corp. (Nasdaq: KOOLD), a leading supplier of innovative products and services that process and store adult stem cells, said today that it has been informed by NASDAQ that the Company is in compliance with all NASDAQ listing standards, including the minimum price bid requirement.

"We are pleased to have retained our presence on the NASDAQ market," said J. Melville Engle, Chief Executive Officer of ThermoGenesis. "We finished fiscal 2010 in strong fashion and are off to a solid start in fiscal 2011 as we execute on our strategies to drive shareholder value," he added.

About ThermoGenesis Corp.ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

The BioArchive® System, an automated cryogenic device, is used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant. AXP® AutoXpress™ Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP™ MarrowXpress™ and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting. The Res-Q™ 60 BMC (Res-Q), a point-of-care system that is designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates. The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, is use

'/>"/>

SOURCE

Advertisement
Advertisement